| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Outline of Final Research Achievements |
Series of Lentiviral vectors were prepared; each carrying different-type of full- and short-version of dystrophin, marker gene, myogenic transcriptional factors, under the control of various combinations of muscle specific promoters and the miR target sequences. The myoD-ER(T), fusion gene with myoD and modified estrogen receptor biding domain for Tamoxifen, was successfully introduced into dermal fibroblasts by lentiviral transduction, and covert themselves to myogenic cells. These cell therapy resources are candidates of genetic modifications by not only viral vectors based technologies and newly developed gene-editing technologies.
|
